CSPC Listed in Global Top 500 Enterprises in R&D Investment

January 11, 2024

Recently, the European Commission's Joint Research Centre has released the 2023 EU Industrial R&D Investment Scoreboard, ranking 2500 companies with the greatest R&D investments globally in fiscal year 2022. A total of 679 companies from the Chinese mainland, including CSPC, were listed.

In terms of R&D investment, CSPC ranked 72nd among all the companies from the Chinese mainland and 389th in the global top 2500, taking a global top 500 spot.

This year, CSPC was also included in the list of global top 25 pharmaceutical enterprises in the R&D pipeline scale released by Citeline, ranking 23rd. CSPC now has more than 130 ongoing innovative drug projects, and it is expected that over 40 blockbuster innovative drugs will be marketed successively in the next five years, benefiting relevant patients.

Previous: CSPC Subsidiary Awarded Provincial Engineering Research Center

Next: VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR IRINOTECAN LIPOSOME INJECTION TO U.S. FDA